1.. Introduction {#S0001}
================

The efficacy of percutaneous coronary intervention (PCI) has improved significantly with the use of drug-eluting stents (DESs). However, the concern regarding their safety, specifically stent thrombosis, is rising. Although the rate of stent thrombosis is generally low, its occurrence is potentially fatal \[[1](#CIT0001)--[3](#CIT0003)\]. Current PCI guidelines recommend dual antiplatelet therapy (DAPT) with aspirin and thienopyridine as the cornerstone of treatment after DES implantation \[[4](#CIT0004),[5](#CIT0005)\]. The first 6--12 months (mo) post--coronary stent implantation hold the highest risk of thrombotic complications \[[1](#CIT0001),[6](#CIT0006),[7](#CIT0007)\]. Therefore, DAPT is recommended during this 'ischemic phase'. The use of DAPT during the 'maintenance phase', however, is associated with an increased bleeding risk \[[5](#CIT0005)\]. Strategies to reduce bleeding risk, such as reducing the DAPT duration, have emerged, especially with the establishment of a new, safer generation of DESs \[[8](#CIT0008),[9](#CIT0009)\]. In contrast, patients with a stenosed stent, diabetes, or low bleeding risk may experience the benefit of prolonged (more than a year) DAPT without a similar bleeding risk \[[8](#CIT0008)--[11](#CIT0011)\].

Multiple randomized clinical trials (RCTs) have evaluated the safety and efficacy of different DAPT durations with conflicting results \[[12](#CIT0012)--[15](#CIT0015)\]. Previous meta-analyses and systematic review have also shown mixed results \[[16](#CIT0016)--[19](#CIT0019)\]. Therefore, we conducted our network meta-analysis to evaluate the safety and efficacy of various DAPT durations in patients undergoing DES implantation.

2.. Methodology {#S0002}
===============

2.1.. Literature search and data source {#S0002-S2001}
---------------------------------------

An electronic literature search was performed independently by two authors (A.A. and Y.Z.) according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) Statement 2015. We comprehensively searched PubMed, Embase, Cochrane Library, and clinicaltrials.gov from inception to 8 March 2018. Any disagreement was resolved by a discussion between the two authors and in consultation with a third author (M.B.). Neither language nor demographic restrictions were applied. Furthermore, references of the relevant studies and meta-analyses were reviewed for possible eligibility. The search terms were: 'drug eluting stent\*', 'DES', 'stent', 'dual antiplatelet', 'DAPT', 'aspirin', 'clopidogrel', 'Plavix', 'P2Y12', 'thienopyridines', 'ticagrelor', 'prasugrel.'

Studies were first screened by their titles and abstracts for eligibility. Then, full texts of the eligible studies were reviewed before exclusion. The search process is detailed in [Figure 1](#F0001). The electronic search was archived through Mendeley and is available on request. Our study was a systematic review and meta-analysis and thus did not require institutional review board (IRB) approval.10.1080/20009666.2018.1562853-F0001Figure 1.Preferred reporting items for systematic reviews and meta-analyses chart of the studies selection process.

2.2.. Study selection and data extraction {#S0002-S2002}
-----------------------------------------

We included only RCTs that compared long-term versus short-term DAPT after PCI and their effect on various clinical outcomes. The duration of DAPT was classified into three categories: 3--6 mo, 12--24 mo, and 24--36 mo. Retrospective studies were excluded to reduce biases and eliminate confounding variables. The main outcome of each included RCT and the baseline patient characteristics are shown in [Tables 1](#T0001) and [2](#T0002).10.1080/20009666.2018.1562853-T0001Table 1.Details of the randomized clinical trials.Name of study/AuthorNumber of patientsFollow up durationTreatment durationStudy populationStudy periodPrimary OutcomeEXCELLENT/Gwon et al. 20121443\*12 months6 months vs 12 monthsExclude recent MI (within 72 h)2008--2009Composite of cardiac death, myocardial infarction, or target vessel revascularizationPRODIGY/Valgimigli et al. 20121443\*24 months6 months vs 24 monthsAny PCI2006--2008Cumulative incidence of death of any cause, nonfatal myocardial infarction, or cerebrovascular accidentRESET/Kim et al. 20122117\*12 months3 months vs 12 monthsAny PCI2009--2010Composite of death from cardiovascular cause, myocardial infarction, stent thrombosis, ischemia-driven target-vessel revascularization, or bleedingOPTIMIZE/Feres et al. 20133119\*12 months3 months vs 12 monthsSTEMI excluded2010--2012Composite of death from any cause, MI, stroke, or major bleedingSECURITY/Colombo et al. 20141399\*21.4 months6 months vs 12 monthsExclude STEMI2009--2014Composite of cardiac death, MI, stroke, definite or probable stent thrombosis, or\
BARC criteria type 3 or 5 bleedingARCTIC-Interruption/Collet et al. 20141259\*\*17 months12 months vs 30 monthsPlanned PCI, no STEMI2011--2012Composite of all-cause death, myocardial infarction, stroke or transient ischemic attack, urgent coronary revascularization, and stent thrombosisDES LATE/Lee et al. 20145045\*\*4 months12 months vs 36 monthsAny PCI2007--2011Composite of death resulting from cardiac causes, myocardial infarction, or strokeDAPT/Mauri et al. 20149961\*17 months12 months vs 30 monthsAny PCI2009--2011Cumulative incidence of definite or probable stent\
thrombosis and of major\
Adverse cardiovascular and cerebrovascular events (defined as the composite of death, myocardial\
infarction, or stroke)OPTIDUAL/Helft et al. 20151385\*\*33.9 months12 months vs 48 monthsAny PCI2009--2013Net adverse clinical events defined as the composite of all-cause mortality, non-fatal myocardial infarction, stroke,\
or major bleedingISAR-SAFE/Schu¨pke. 20154000\*\*6.6 months6 months vs 12 monthsAny PCI2008--2014Composite of death, myocardial infarction, stent thrombosis (definite or probable), stroke, or TIMI major bleedingITALIC/Gilard et al. 20151822\*12 months6 months vs 24 monthsAny PCI2012--2013Composite of death, MI, repeat emergency TVR, stroke, or major\
TIMI bleedingI LOVE IT-2/Han et al. 20161829\*18 months6 months vs 12 monthsAny PCIn/aCardiac death, target vessel myocardial\
infarction, or clinically indicated target lesion revascularizationIVUS-XPL/Hong et al. 20161400\*12 months6 months vs 12 monthsAny PCI2010--2014Composite of cardiac death myocardial infarction, stroke, or TIMI major bleedingNIPPON/Nakamura et al. 20173307\*\*14.5 months6 months vs 18 monthsAny PCI2011--2015Composite of all cause death, Q-wave or non--Q-wave MI,\
cerebrovascular events, and major bleeding events.OPTIMA-C/Lee et al. 20171367\*12 months6 months vs 12 monthsSTEMI excluded2011--2014Composite of cardiac death, Target vessel related MI, Ischemia-driven target lesion revascularizationSMART-DATE/Hahn et al. 20182712\*18 months6 months vs 12 monthsAcute ACS PCI2012--2015Composite of major adverse\
cardiac and cerebrovascular events, defined as a composite of all-cause mortality, myocardial infarction, or stroke[^1]10.1080/20009666.2018.1562853-T0002Table 2.Demographic features. DurationAge(year)Male (n)DMHTNDyslipidemiaCurrent smokerPrevious MIPrevious PCIPrevious CABGCVAPVDStable anginaUnstable Angina/NSEMISTEMIEXCELLENTLong 72162.4 ± 10.44612785325501862762748-34634926Short 72263.0 ± 9.647027252554319847671147-35335019PRODIGY\-\-\-\-\-\-\-\-\-\-\-\-\-\--RESETLong 105862.4 ± 9.866530565063424117326\--490422146Short 105962.4 ± 9.468231666061126719372\--471432156OPTIMIZELong 155661.9 ± 10.69825491371952269542279128384614384-Short 156361.3 ± 10.49925541350953290541327111384313484-SECURITYL 717 S 682Long 71765.5 ± 10.155122351043617214411639\--368229-Short 68264.9 ± 10.252921650844613913513238\--341213-ARCTIC-InterruptionLong 63564 ± 75032223884261521862493538\-\-\--Short 62464 ± 85041983764281471972734728\-\-\--DES LATELong 253162.5 ± 10.017497091479 693103313-15-1011930/268314Short 251462.3 ± 10.117497091423 72292276-89-956971/266314DAPT trialLong 502061.8 ± 10.2377815563796-1222109215185681552841882838/776534Short 496161.6 ± 10.1365714813649-1210102615295811692841870825/767511OPTIDUAL trialLong 69564.1 ± 10.8568213396-42511918037293424066/9974Short 69064.2 ± 11.5547222417-39912218635254520763/11782ISAR-SAFELong 200367.2 ± 6.5161248418301748306491-149\--956438/203166Short 199767.2 ± 7.9161149517971747292516-152\--969429/207158ITALICLong 91061.5 ± 11.17213445896114801342054526-378149/653Short 91261.7 ± 10.97373315956124641422206125-375143/671I-LOVE-IT 2Long 92060.0 ± 10.06322035962153521456048710139520/98126Short 90960.4 ± 10.26112115542303331567748413130527/103122IVUS-XPLLong 70164 ± 9494257455456165297314\--358231112Short 69963 ± 9470249443473171347222\--356237106NIPPONLong 165367.2 ± 9.9131263512091132967159432294844734330/26196Short 165467.4 ± 9.6130461911771130990201413224162805296/33198OPTIMA-CLong 68464.4 ± 10.34642034371951842571\-\--339254/90-Short 68362.810.84781994262041841859\-\--336253/95-SMART-DATELong 135562.2 ± 11.9102837965433653623\*5258\--416/425514Short 135762.0 ± 11.5101636566932250630\*6552\--420/428509[^2]

2.3.. Quality assessment {#S0002-S2003}
------------------------

We performed a quality assessment for the included RCTs. We assessed the included RCTs for random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other biases. We classified studies as low-risk for bias only if all the described items were adequately described as low-risk. Quality assessment results are attached in the online supplemental data.

2.4.. Data extraction {#S0002-S2004}
---------------------

Two authors (A.A., M.B.) independently and separately extracted the data from the included studies into a predesigned form. Any disagreement was resolved by a discussion between the two reviewers and a third investigator (Y.Z.).

2.5.. Outcomes {#S0002-S2005}
--------------

The primary outcome was the incidence of major adverse cardiac events (MACE) and incidence of major bleeding between different durations of DAPT. The definitions of MACE and major bleeding events are shown in **supplementary material Tables S1**.

2.6.. Data synthesis {#S0002-S2006}
--------------------

We conducted our network meta-analysis using the Markov Chain Monte Carlo (MCMC) simulation with a little informative prior distributions and likelihood function to derive the posterior distribution of the parameter. We assessed convergence using the Brooks-Gelman-Rubin method as well as the Monte-Carlo error to check if the error was \<5% of the standard deviation of the effect estimates and between-study variance. Random effects for the consistency model were reported as odds ratios (ORs) and Bayesian 95% credible intervals (CI). We converted the relative treatment effects to a probability of the best, second best, third best, and so on, as well as the ranking of each treatment. We combined both results to estimate the surface under the cumulative ranking curve (SUCRA). Inconsistency was assessed by comparing the deviance residuals and deviance information criteria (DIC) statistics in fitted consistency and inconsistency models to identify any loops in the treatment network where inconsistency was present. We analyzed our data using NetMetaXL v1.6.1 and WinBUGS software v1.4.3 (Imperial College and Medical Research Council).

3.. Results {#S0003}
===========

Sixteen RCTs were included in the analysis with a total of 42,993 patients; 30.1% were treated for 3--6 mo, 46.9% for 12 mo, and 23% for 24--48 mo. The baseline demographics are shown in [Table 2](#T0002). The mean age of patients included in the trials was 63.1 ± 10.1 years. Overall, 31.3% of patients had diabetes and 67.3% had hypertension. The procedural characteristics of each RCT are shown in **supplementary material Tables S2**. The most stented artery was the left anterior descending (LAD) artery. Both first- and second-generation stents were used, in various proportions, in these RCTs.

There was a significant improvement in MACE in patients treated with DAPT for 24--48 mo following DES when compared with those treated for 3--6 mo (OR 0.75; 95% CI \[0.58--0.97\]). In contrast, improvement in MACE was not significantly different when those treated with 24--48 mo of DAPT following DES were compared with those treated with 12 mo of DAPT (OR 0.86; 95% CI \[0.69--1.08\]). Also, there was no significant improvement in MACE in patients treated with 12 months of DAPT when compared with patients treated with DAPT for 3--6 months (OR 0.87, 95% CI \[0.72--1.05\]), as illustrated in [Figure 2](#F0002).10.1080/20009666.2018.1562853-F0002Figure 2.Forest plots summarizing the major adverse cardiac events between the competing treatments duration. Random effects model was used to report the odds ratios (ORs) with 95% credible intervals (CIs).

The effect of duration of DAPT following DES on the bleeding risk was also studied. Compared with patients treated with 24--48 mo of DAPT following DES, those treated with either 3--6 mo (OR 0.32, 95% CI \[0.17--0.54\]) or 12 months of DAPT (OR 0.43, 95% CI \[0.27--0.63\]) experienced lower bleeding risk. On the other hand, there was no significant improvement in risk of major bleeding when 12 months of DAPT was compared with 3--6 months of DAPT (OR 0.75, 95% CI \[0.50--1.10\]), as illustrated in [Figure 3](#F0003).10.1080/20009666.2018.1562853-F0003Figure 3.Forest plots summarizing the major bleeding events between the competing treatments duration. Random effects model was used to report the odds ratios (ORs) with 95% credible intervals (CIs).

4.. Discussion {#S0004}
==============

In the present network meta-analysis of 16 RCTs to evaluate the safety and efficacy of various DAPT durations in DES-treated PCI patients, we had several notable findings \[[12](#CIT0012)--[15](#CIT0015),[20](#CIT0020)--[31](#CIT0031)\]. First, long-duration DAPT (≥24 mo) reduces the composite ischemic vascular events significantly when compared with short-duration DAPT (3--6 mo). Second, there is a trend of improved composite ischemic vascular events with longer DAPT as 12 mo was better than 3--6 mo and ≥24 mo was better than both 3--6 mo and 12 mo. Third, there is a higher bleeding risk when longer duration DAPT is used, as there was a significant increase in major bleeding with long-duration DAPT (≥24 mo) when compared with shorter duration DAPT (3--6 mo and 12 mo). Thus, our findings support the use of long-duration DAPT in patients with high risk of thrombotic events and short-duration DAPT in high bleeding-risk patients.

Despite the advances in the treatment of coronary artery disease, recurrent stent thromboses remain problematic \[[32](#CIT0032),[33](#CIT0033)\]. The introduction of DAPT (aspirin and a P2Y12 receptor antagonist) has mitigated the risk of early and late thrombosis after coronary stent implantation, yet the duration of DAPT remains controversial \[[34](#CIT0034)\]. Although most of the previously published meta-analyses have supported the use of short-duration DAPT because of the lower associated bleeding risk without an apparent increase in ischemic vascular events, some meta-analyses were consistent with our finding and supported the use of longer durations of DAPT after DES implantation to reduce ischemic vascular events \[[19](#CIT0019),[35](#CIT0035)\]. The time-dependent nature of DAPT on risk of ischemic vascular events has also been demonstrated in a previous meta-analysis \[[36](#CIT0036)\].

Six trials evaluated the efficacy of DAPT when used for more than 12 mo \[[12](#CIT0012),[13](#CIT0013),[23](#CIT0023),[24](#CIT0024),[27](#CIT0027),[31](#CIT0031)\]. All of them showed a lower incidence of composite ischemic events compared to shorter durations of DAPT with the exception of Lee et al and Valgimigli et al, who showed a higher incidence of these events with long DAPT \[[12](#CIT0012),[27](#CIT0027)\]. A recently published individual data meta-analysis by Lee et al may explain the unexpected findings in these two studies, however \[[37](#CIT0037)\]. The majority of deaths in these trials were associated with a higher rate of Type II MI, a condition that is not affected by DAPT, indicating that many of these deaths may not have been related to a true cardiac event \[[38](#CIT0038)\]. It should be noted that the DAPT Trial -- the largest of these trials -- reported a significantly lower incidence of vascular events with long DAPT \[[13](#CIT0013)\]. Furthermore, a subgroup analysis of patients treated by everolimus-eluting stents -- the most commonly used stent -- resulted in significant reduction of stent thrombosis and MI \[[39](#CIT0039)\].

In our study, there was no significant difference in the rate of ischemic events with 12 mo of DAPT, which is the current recommended duration after DES implantation, when compared with using DAPT for 6 mo or less following DES \[[5](#CIT0005)\]. This result was inconsistent with three of the included trials \[[21](#CIT0021),[22](#CIT0022),[28](#CIT0028)\]. This incongruity could be explained by the inclusion of low-risk patients and short duration of follow-up implemented by these trials. Also, several trials were limited by low event rates, which raise the possibility of bias \[[22](#CIT0022),[28](#CIT0028)\]. In contrast, Hahn et al included only patients with acute coronary syndrome (ACS) and showed a lower rate of composite ischemic events in the 12 mo DAPT group \[[15](#CIT0015)\]. This may highlight the importance of longer duration DAPT in patients with ACS, as they have a higher rate of recurrent ischemic events than patients with stable coronary artery disease \[[32](#CIT0032),[33](#CIT0033)\]. More trials with exclusively ACS patients are required, however, before solid conclusions can be made regarding the optimal duration of DAPT after DES implantation in such patients.

In our meta-analysis, the benefit of prolonging DAPT was precluded by a higher risk of bleeding, which was consistent across all of the included trials. Although bleeding risk has been associated with higher mortality, both a recently published analysis by Udell et al and Mauri et al concluded that the risk of fatal bleeding was not significantly higher in a longer duration DAPT arm when compared with a shorter duration DAPT arm \[[13](#CIT0013),[16](#CIT0016),[40](#CIT0040)\]. Furthermore, one study showed a comparable risk of noncardiac death between 6 mo and 12 mo of DAPT, even though the major bleeding risk was higher with longer DAPT \[[37](#CIT0037)\]. Thus, it remains controversial as to whether or not reported bleeding risk should affect clinical decision-making when it comes to duration of DAPT following DES.

Although our results support longer duration DAPT after DES implantation to reduce risk of ischemic events, it is important to note that there has been a recent influx of new generation DESs, which inherently carry different thrombosis risks, as well as several different combinations of DAPT.

4.1.. Limitations {#S0004-S2001}
-----------------

Our analysis has some limitations that should be acknowledged. First, we did not have access to patient-level data. Second, the definition of MACE varied between the clinical trials; however, we could not find any significant heterogeneity in the analysis (I^2^ \< 15). Third, there were inconsistencies in the definition of bleeding events among the included studies. Fourth, the included trials assessed different CAD presentations (stable vs ACS). Finally, clopidogrel was the main thienopyridine used in most of the included trials; therefore, generalizability of the current results to other P2Y12 blockades is limited.

5.. Conclusions {#S0005}
===============

In patients who undergo DES implantation, longer durations of DAPT after DES implantation are associated with lower rates of composite ischemic vascular events, especially with durations longer than 24 mo. Longer duration DAPT is associated with a higher rate of bleeding, however.
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###### Supplemental Material

[^1]: Abbreviation. ARCTIC; Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Interruption Versus Continuation of Double Antiplatelet Therapy; BARC: Bleeding Academic Research Consortium; DAPT: Dual Antiplatelet Therapy; DES LATE: Duration of Clopidogrel Therapy After Drug-Eluting Stent; EXCELLENT: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting; I LOVE IT: Evaluate Safety and Effectiveness of the Tivoli DES and the Firebird DES for Treatment of Coronary Revascularization; ISAR-SAFE: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting; MI: myocardial infarction; ITALIC: Is There A LIfe for DES After Discontinuation of Clopidogrel; IVUS-XPL: Impact of Intravascular Ultrasound Guidance on Outcomes of XIENCE PRIME Stents in Long Lesions; NIPPON: Nobori Dual Antiplatelet Therapy as Appropriate Duration; OPTIDUAL: Optimal Duration of Dual Antiplatelet Therapy After Drug-eluting Stent Implantation; OPTIMA-C: Optimal Duration of Clopidogrel in Second-Generation Drug-Eluting Stents; OPTIMIZE: OPTIMIZE IDE for the Treatment of ACS; PCI: Percutaneous coronary intervention; PRODIGY: Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia; RESET: REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation; SECURITY; Second-Generation Drug-Eluting Stent Implantation Followed by 6- Versus 12-Month Dual Antiplatelet Therapy; SMART-DATE: Safety of 6-month Duration of Dual Antiplatelet Therapy After Acute Coronary Syndromes; STEMI: ST-elevation myocardial infarction; TIMI: Thrombolysis in Myocardial Infarction.

    \*mean

    \*\*median

[^2]: Abbreviation. ARCTIC; Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Interruption Versus Continuation of Double Antiplatelet Therapy; CAPG: coronary artery bypass graft; CVA: Cerebrovascular accident; DAPT: Dual Antiplatelet Therapy; DES LATE: Duration of Clopidogrel Therapy After Drug-Eluting Stent; DM: Diabetes Meletus; EXCELLENT: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting; HTN: Hypertension; I LOVE IT: Evaluate Safety and Effectiveness of the Tivoli DES and the Firebird DES for Treatment of Coronary Revascularization; ISAR-SAFE: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting; MI: myocardial infarction; ITALIC: Is There A LIfe for DES After Discontinuation of Clopidogrel; IVUS-XPL: Impact of Intravascular Ultrasound Guidance on Outcomes of XIENCE PRIME Stents in Long Lesions; Long: long duration of DAPT; MI: myocardial infarction; NIPPON: Nobori Dual Antiplatelet Therapy as Appropriate Duration; NSTEMI: Non-ST-elevation myocardial infarction; OPTIDUAL: Optimal Duration of Dual Antiplatelet Therapy After Drug-eluting Stent Implantation; OPTIMA-C: Optimal Duration of Clopidogrel in Second-Generation Drug-Eluting Stents; OPTIMIZE: OPTIMIZE IDE for the Treatment of ACS; PCI: Percutaneous coronary intervention; PRODIGY: Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia; PVD: Peripheral vascular disease; RESET: REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation; SECURITY; Second-Generation Drug-Eluting Stent Implantation Followed by 6- Versus 12-Month Dual Antiplatelet Therapy; Short: Shorter duration of DAPT; SMART-DATE: Safety of 6-month Duration of Dual Antiplatelet Therapy After Acute Coronary Syndromes; STEMI: ST-elevation myocardial infarction.

    \*number of both previous PCI and CABG.
